Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis
ConclusionRTX may be an effective and relatively safe treatment choice in patients with IIMs, especially for refractory cases. However, further verification via randomized controlled trials is warranted.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Autoimmune Disease | China Health | Databases & Libraries | Dermatology | Dermatomyositis | Germany Health | Inclusion-Body Myositis | Polymyositis | Rituxan | Skin | Study | USA Health